Article Sidebar

PDF
Issue: Vol. 567 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v567i1.19270
Date Published: 05/11/2026
Views 43
Downloads 26
How to Cite
Phạm, Q. T., Hoàng, T. T. N., & Nguyễn, Q. T. (2026). ANTI-A/B IMMUNE ANTIBODY TITERS IN ABO-INCOMPATIBLE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Vietnam Medical Journal, 567(1). https://doi.org/10.51298/vmj.v567i1.19270

ANTI-A/B IMMUNE ANTIBODY TITERS IN ABO-INCOMPATIBLE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Quang Thịnh Phạm1,2, , Thị Thanh Nga Hoàng1, Quang Tùng Nguyễn1,2
1 Viện Huyết học – Truyền máu Trung ương
2 Trường Đại học Y Hà Nội

Main Article Content

Abstract

Objective: To determine anti-A/B immune antibody titers and evaluate their associations with the time to ABO blood group conversion and post-transplant RBC transfusion requirements.


Subjects and Methods: Cross-sectional analytical study included 24 patients undergoing allogeneic hematopoietic stem cell transplantation with ABO blood group incompatibility at the National Institute of Hematology and Blood Transfusion from January 2025 to June 2026.


Results: Immune anti-A/B antibodies were detected before transplantation in 54.2% of patients, while 37.5% of patients had immune anti-A/B antibodies reactive with donor red blood cells. The median pre-transplant immune anti-A/B antibody titer was 16 (IQR:16-64), and the median duration of antibody persistence was 28 days (IQR:14-39). Higher pre-transplant immune anti-A/B antibody titers were associated with prolonged antibody persistence (rs=0,841, p=0,005) and increased post-transplant red blood cell transfusion requirements (p=0,004).


Conclusion: Determination of pre-transplant immune anti-A/B antibody titers and monitoring their post-transplant persistence may help predict post-transplant RBC transfusion requirements.

Keywords

Anti-A/B immune antibody, allogeneic hematopoietic stem cell transplantation, transfusion medicine

Article Details

References

1. Adkins BD, Andrews J, Sharma D, Hughes C, Kassim AA, Eichbaum Q. Low rates of anti-recipient isohemagglutinins in ABO incompatible hematopoietic stem cell transplants. Transfusion and Apheresis Science. 2021;60(1):102965.
2. De Santis GC, Garcia-Silva AC, Dotoli GM, de Castro PT, Simões BP, Covas DT. Higher anti-A/B isoagglutinin titers of IgG class, but not of IgM, are associated with increased red blood cell transfusion requirements in bone marrow transplantation with major ABO mismatch. Clinical Transplantation. 2017;31(4):e12913.
3. Griffith LM, McCoy JP Jr, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplantation. 2000;25(2):179-184.
4. Lemaire B, Combescure C, Chalandon Y, Vuilleumier N, Waldvogel Abramowski S. Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2022;57(9):1405-1410.
5. Olsson ML, Westman JS. ABO and Other Carbohydrate Blood Group Systems. In: Cohn CS, Delaney M, Johnson ST, Katz LM, Schwartz J, editors. AABB Technical Manual. 21st ed. Bethesda (MD): AABB Press; 2023.
6. Stussi G, Muntwyler J, Passweg JR, Seebach L, Schanz U, Gmür J, et al. Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation. 2002;30(2):87-93.
7. Worel N. ABO-mismatched allogeneic hematopoietic stem cell transplantation. Transfusion Medicine and Hemotherapy. 2016;43(1):3-12.
8. Yu ZQ, Gao ZF, Li HY. Study on serological blood group conversion rule and clinical blood transfusion in allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2012;33(8):637-641.